Ryvu presents RVU602 data and Ryvu Therapeutics stock is valued at PLN 404.1 million

Published on 10/15/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

RVU602 delivered 100 percent efficacy in tumor cells on October 14, 2026. Ryvu Therapeutics stock costs EUR 4.00 on October 15, 2026.

RVU602 evidence and study context

Ryvu reported 100 percent efficacy for an RVU602 ADC in patient-derived TROP2-positive cancer cells on October 14, 2026.
RVU602 was tested across 272 cancer cell lines and achieved complete responses in 83 percent of animals under one dosing schedule.
Ryvu Therapeutics stock was trading at EUR 4.00 at 1:07 p.m. CEST at Lang & Schwarz on October 15, 2026.

Ryvu Therapeutics, PLSELVT00013, Illustration mit AI erstellt.

Ryvu Therapeutics (ISIN PLSELVT00013) reported 100 percent efficacy for RVU602 antibody-drug conjugates in patient-derived TROP2-positive triple-negative breast cancer cells on October 14, 2026. According to Bankier, the company presented the preclinical findings at the World ADC Congress in San Diego.

RVU602 shows a new angle

The data give Ryvu a differentiated research angle because RVU602 is designed as a payload outside the two mechanisms used widely in existing ADCs. The company tested the compound with four clinically validated antibodies, including sacituzumab, cetuximab, telisotuzumab and trastuzumab.

Stockwatch reported that RVU602 showed activity across 272 cancer cell lines. In the HCC70 tumor model, the sacituzumab-RVU602 combination produced complete responses in 100 percent of animals after two weekly 10 mg/kg doses and in 83 percent after four 5 mg/kg doses twice a week.

What did the models show?

The strongest signal was the contrast between the two dosing schedules: the lower-dose regimen produced an 83 percent complete-response rate, while the higher weekly regimen reached 100 percent. The patient-derived cell tests also showed activity at EC50 values from 0.4 to 7.5 nM and selectivity of 30 to 250 times versus the isotype control.

The pipeline carries clinical risk

For investors, the preclinical result adds platform value but does not remove development risk. A September 15, 2026 update ended the Phase 2 RIVER-52 trial of RVU120 in acute myeloid leukemia and high-risk myelodysplastic syndromes, according to The Globe and Mail. That contrast makes RVU602 execution and partnering progress important next markers.

Stock price and company value

Ryvu Therapeutics stock was trading at EUR 4.00 at Lang & Schwarz on October 15, 2026 at 1:07 p.m. CEST. The Warsaw-listed company had a market capitalization of PLN 404.1 million, while its 52-week range stood at PLN 13.64 to PLN 31.90 on October 15, 2026. The further course of trading is shown by the continuously updated real-time quote of Ryvu Therapeutics stock.